(UroToday.com) The European International Kidney Cancer Symposium 2021 Virtual Meeting included a systemic therapy session and a presentation by Dr. Toni Choueiri discussing circulating biomarkers for potential adoption in renal cancer.
(UroToday.com) The European International Kidney Cancer Symposium 2021 Virtual Meeting included a systemic therapy session and a presentation by Dr. Thomas Powles discussing tissue-based biomarkers for potential clinical adoption in renal cancer.
(UroToday.com) In the American Urologic Association (AUA) Course of Choice Lecture at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Morgan discussed the role of genetic testing in prostate cancer across the spectrum of the disease natural history from early detection to the treatment of localized disease and castration-resistant prostate cancer (CRPC).
(UroToday.com) Disparities in health care in the United States are widespread and prevalent – racial disparities affecting African Americans are particularly long-standing and consequential. In the context of prostate cancer, it has been long recognized that the incidence is higher among African American men. However, differences in prostate cancer mortality according to race are somewhat […]
(UroToday.com) In the United States, cancers of the kidney and renal pelvis comprise the 6th most common newly diagnosed tumors in men and 10th most common in women, with new diagnoses exceeding 65,000 patients annually. For patients with large or locally advanced renal tumors, radical nephrectomy (RN) is a commonly used treatment approach. Perioperative mortality ranges from 0.5-3.6%. Mortality risk […]
(UroToday.com) In the Bedford Waters Lecture at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Litwin presented on the Critical Pursuit of Social Justice in Urology.
(UroToday.com) Advanced urothelial carcinoma carries among the worst prognoses for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy. However, even with this treatment, rates of recurrence and disease progression are high and overall survival is quite short due to the development of chemotherapy resistance. In the JAVELIN Bladder 100 […]
(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. This proliferation of first-line treatment choices has had meaningful effects on second-line treatment selection.
(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. While the proliferation of treatment options has provided ample treatment choice, deciding among these can be difficult. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Brian Rini presented […]
Androgen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss (CTIBL), which impairs the patient’s quality of life. In patients with nonmetastatic castration-sensitive prostate cancer (M0CSPC) who already have osteoporosis before starting ADT, appropriate bone-modifying agent intervention must be performed in parallel, as the patient has […]
